Since 1995, NI Research has provided its unique brand of direct and honest analysis to the pharmaceutical industry and the financial institutions who provide the industry’s fiscal lifeblood. We focus solely upon neurological and psychiatric therapeutics, and we cover those more comprehensively and candidly than anyone else. NI Research does not soft-pedal and euphemize its reviews in the service of maximizing corporate enrollment in other ventures, we have built our reputation on being thorough and straightforward. But we also believe that covering both the science and the business in this, the most exciting area of medical therapeutics development, does not have to be boring. There is more than a little surreal entertainment available in following this sector, and we believe in leavening our coverage with the humor that is too often completely drained from its literature and coverage.

The core of NI Research consists of two publications and 'Second Opinion', our consultation service:

1. Our flagship monthly journal, NeuroPerspective (formerly NeuroInvestment) has set the standard for independent analysis of the neurotherapeutics area since 1995.
2. NeuroLicensing focuses on the major and midsize companies that are the primary resources for partnering/inlicensing novel CNS programs.
3. 'Second Opinion' provides consultation to companies regarding strategic development, including the identification of inlicensing candidates and options for outlicensing.